Boston, MA 06/24/2013 (wallstreetpr) – The share price of Array Biopharma Inc (NASDAQ:ARRY) is currently trading at $4.92, down by 1.70%. The openings price of the share is $4.92 per share. The shares of the company had been trading in the range of $4.86 to $4.98 per share during the day. The shares of the company had thereby adjusted to 52 week high price level of $6.56 per share and the 52 week low price level of the company is at $3.25 per share.
Array BioPharma Inc. is a biopharmaceutical company focused on the development, commercialization and discovery of small molecule drugs to treat patients afflicted with inflammatory diseases and cancer. The drug development includes clinical candidates that are designed to regulate therapeutically target pathways.
ARRY has announced the results interim from ARRY-520, an ongoing clinical trial in multiple myeloma were presented at Congress European Association of Hematology in Stockholm, Sweden on 2013. The company presented the information on a patient selection potentially marker for ARRY-520, which is highly targeted inhibitor of KSP highly sensitive mechanism of action to treat MM from other drugs used continues to advance in clinical trials.
“The combination of ARRY-520 with Kyprolis is well tolerated and reversible neutropenia is the most common adverse event and does not appear to be relative to the observed events for either drug alone,” said M.D Mr. Jatin J.Shah, Assistant Professor Myeloma, A dissection of Cancer Medicine, MD Anderson Cancer Center and The University of Texas.
The ARRY shares of had thereby been trading in volumes with nearly 584.46 million trades being executed on Friday against an average volume of 1.67 million shares per day. The company presently holds 116.78 million shares outstanding in the market with an institutional ownership of 80 percent of its holdings.
